Pharmaceutical Business Intelligence

  • Find generic sources and suppliers
  • Predict branded drug patent expiration
  • Drug patents and clinical trials in dozens of countries

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 4,442,101

« Back to Dashboard

Summary for Patent: 4,442,101

Title: Sesquihydrate of naphthyridine derivative, and process for the preparation thereof
Abstract:Novel 1-ethyl-6-fluoro-1,4-dihyono-4-oxo -7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid.sesquihydrate (ATT-2266.sesquihydrate). The aforesaid compound can be prepared by heating 1-ethyl-6-fluoro-1,4-dihydro-4-oxo -7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid at a temperature above about 60.degree. C. in the presence of water in an amount sufficient to form the sesquihydrate. This sesquihydrate is much more stable than the anhydrate and the trihydrate and is superior to the anhydrate in the rate of dissolution and transference into the body through the intestines. Thus, it is especially useful as a pharmaceutical compound.
Inventor(s): Ichihashi; Hitoshi (Kyoto, JP), Tanaka; Terukazu (Osaka, JP), Imasato; Yu (Toyonaka, JP)
Assignee: Dainippon Pharmaceutical Co., Ltd. (Osaka, JP) Laboratoire Roger Bellon (Neuilly sur Seine, FR)
Application Number:06/345,916
Patent Claim Types:
see list of patent claims
Compound; Use; Process; Composition;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,442,101

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan56-20749Feb 13, 1981

International Patent Family for Patent: 4,442,101

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia547082► Subscribe
Australia8017382► Subscribe
Canada1216292► Subscribe
Czechoslovakia254958► Subscribe
Czechoslovakia8200998► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.